. Author manuscript; available in PMC: 2014 Sep 1.

Published in final edited form as: Psychopharmacology (Berl). 2013 Apr 6;229(1):83–94. doi: 10.1007/s00213-013-3088-7

Table 2.

Effects of yohimbine on catecholamine metabolite levels and autonomic function

Measure (n=23 or as shown)	Baseline	Maximum Change (Δ)	Univariate Effect Size for Δ	Repeated measures
Measure (n=23 or as shown)	Baseline	Maximum Change (Δ)	Univariate Effect Size for Δ	F (DF)	P
MHPG (n=21), ng/mL	4.47 ± 1.38	1.60 ± 2.12	0.75	2.64 (4,68)	0.041
VMA (n=13), ng/mL	6.90 ± 2.20	1.99 ± 1.18	1.66	11.7 (4,44)	0.00001
HVA (n=22), ng/mL	8.89 ± 2.57	0.31 ± 2.15	0.14	0.66 (4,84)	0.63
Systolic BP, mm Hg	117.1 ± 11.1	11.65 ± 13.6	0.86	9.72 (4,88)	0.00001
Diastolic BP, mm Hg	73.2 ± 8.0	5.7 ± 9.2	0.62	2.47 (4,88)	0.05
Pulse, b/min	68.3 ± 9.9	7.09 ± 10.8	0.65	3.58 (4,88)	0.009
Temperature, degrees F	97.4 ± 0.7	0.46 ± 1.24	0.37	1.82 (4,88)	0.13

Means are given with standard deviations. Analysis for MHPG used education as covariate. Effect size (for Δ) is the effect size for the maximum difference between net change from baseline with administration of yohimbine versus placebo. Significant effects (p < 0.05) are shown in bold face.